Novo Nordisk A/S (NVO) vs State Street SPDR S&P 500 ETF (SPY)

Over the past 10 years, NVO lagged SPY — 7.59% vs 14.98% annualized total return (price plus dividends).

A side-by-side comparison of Novo Nordisk A/S and State Street SPDR S&P 500 ETF across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 31, 2026. Differences are shown without an overall score or investment verdict.

Compare
Different business models: NVO is classified in Healthcare; SPY is classified in Financial Services. Margin, capital intensity, and valuation differences should be interpreted in that sector context.

Total returnNVO vs SPY

growth of $100 · dividends reinvested · last 30y
NVO +10806.6%SPY +1888.1%NVO compounded faster
Log scale — wide-divergence pair
1001k10k100kStart $100200120062011201620212026$10,907$1,988
NVO SPY

Metrics side by side

Did NVO beat SPY?

Over the past 10 years, NVO lagged SPY — 7.59% vs 14.98% annualized total return (price plus dividends).

Total return (annualized)

MetricNVOSPY
Total return (1Y)4.60%19.51%
Total return CAGR (3Y)-14.22%19.20%
Total return CAGR (5Y)2.46%12.76%
Total return CAGR (10Y)7.59%14.98%

SPY is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Frequently asked

Has NVO beaten SPY?
Over the past 10 years, NVO lagged SPY — 7.59% vs 14.98% annualized total return (price plus dividends).

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 31, 2026.